Background: Parkinson's disease (PD) is a neurodegenerative disorder with a prevalence
increasing with age. Oxidative stress and glutamate toxicity are involved in its …

Environmental toxins are harmful substances detrimental to humans. Constant exposure to
these fatal neurotoxins can cause various neurodegenerative disorders. Although …

Safinamide (Xadago®) is an orally active, selective, reversible monoamine oxidase-B
inhibitor with both dopaminergic and non-dopaminergic (glutamatergic) properties. In the …

Abstract Parkinson's disease (PD), the second most common neurodegenerative disorder, is
characterized by cardinal motor impairments, including akinesia and tremor, as well as by a …

Safinamide (Xadago®) is an oral α-aminoamide derivative developed by Newron for the
treatment of Parkinson's disease (PD). The drug has both dopaminergic properties (highly …

Abstract Parkinson's disease (PD), a neurodegenerative disorder, is traditionally classified
as a movement disorder. Patients typically suffer from many motor dysfunctions. Presently …

Highlights•Safinamide is a novel MAO-B inhibitor and a Calcium channel blocker
drug.•Safinamide improves OFF-time and ON-time with no-troublesome dyskinesia's in …

Safinamide (Xadago™) is an oral α-aminoamide derivative marketed for the treatment of
Parkinson's disease (PD). The drug has both dopaminergic properties, namely highly …

The symptoms of Parkinson's disease (PD) reflect disruptions of a number of brain
neurotransmitter systems of varying type and degree. Pharmacological agents with multiple …

Abstract Introduction Patients with Parkinson's disease (PD) experience various motor and
non-motor symptoms. We conducted a post hoc analysis of a Japanese phase 2/3 study of …